Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1995| September  | Volume 16 | Issue 3  
    Online since May 30, 2009

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Pemphigus vulgaris and carcinoma of ovary , a case report and review of literature.
M Sandhu, L Kumar, S Kumar
September 1995, 16(3):168-173
The association of pemphigus vulgaris and carcinoma of the ovary is extremely rare. A 47 year old lady was diagnosed to have pemphigus; the lesions responded to high dose corticosteroids and cyclophosphamide therapy. Twenty one months later she was detected to have an enlarged right supraclavicular lymph node, right pleural effusion, ascites and an adnexal mass. Investigations-lymph node biopsy, pleural fluid cytology, CA-125 measurements and CAT scan of abdomen and pelvis confirmed the primary ovarian cancer with disseminated disease-FIGO stage IV. She is currently on chemotherapy with cisplatin and cyclophosphamide and has shown significant response. Patients with pemphigus vulgaris when suspected should be investigated to exclude the possibility of a malignant neoplasm as an early diagnosis may improve the prognosis.
[ABSTRACT]   Full text not available   
  789 0 -
Central nervous system toxicity of high dose cytosar(hdac) : report of 2 cases and review of literature.
R Kamble, B Kslam, L Kumar, V Kochupillai
September 1995, 16(3):177-182
High dose cytosine arabinoside(2-3 gm/m2 12 hourly for 8-10 doses) is often used as consolidation therapy for the management of acute myeloid leukemia(AML). Cytosine arabinoside(Ara-C) in this dose, produces significant neurotoxocity and life threatening myelotoxicity. Over the last two years, 15 patients were administered Ara-C in the dose of 1.5-2 gms/m2 12 hrly x 10 doses as post remission consolidation therapy, three(20 percent) died due to septicemia, secondary to myelotoxicity; 2(including one who died: 13 percent) developed grade II to III neurotoxicity. Neurotoxic complications of high dose Ara-C are discussed in detail. Since intermediate dose Ara-C (0.5-1.0 gms/m2 12 hrly x 8-10 doses) is found to be as effective as high dose Ara-C, such dose is recommended to avoid high morbidity and mortality related to high dose Ara-C.
[ABSTRACT]   Full text not available   
  712 0 -
A comparative study of induction chemotherapy and radiotherapy versus radiotherapy alone in non small cell lung cancer : the safdarjung hospital experience.
R Sharma, V Bajpai, KK Mukhopadhaya, KT Bhowmik
September 1995, 16(3):156-161
Patients with Stage III Non-small Cell Lung Cancer(NSCLC) continue to pose a therapeutic problem with poor cure rates. In an effort to improve upon the results of treatment in locally advanced NSCLC, a randomized trial of induction chemotherapy and radiotherapy versus radiotherapy alone, was conducted at Safdarjang Hospital, New Delhi from March 1992 to February 1994. The study group treatment protocol consisted of induction chemotherapy comprising of MitomycinC 6mg, mw, Ifosfamide 2 gm/m2 with Mesna and Cisplatinum 50 mg/m2 after prior hydration(MIC). After completing 3 cycles of chemotherapy patients received radiotherapy to the primary lesion and mediastinum to a dose of 50-60 Gy in 5-6 weeks. The control group received radiotherapy alone to the primary lesion and mediastinumm to a dose of 55-65 Gy in five and half to six and half weeks. The 180 patients with histologically proven stage III NSCLC were randomized to receive either the study protocol or radiotherapy alone. Of the 90 patients enrolled into the study group, 6(6.7 percent) patients had complete response and 40(44.4 percent) partial response with 3 cycles of induction chemotherapy. On completion of study protocol treatment, the overall response obtained was 62.2 percent, i.e., 13(14.4 percent) patients had complete response and 43(47.8 percent) had partial response. In the 90 patients in control group 3(3.3 percent) patients had complete response while 39(43.3 percent) had partial response. Thus the overall response was 46.6 percent in the control group. Mean duration of response observed in the study group was 10.6 months as against 6.8 months in control group. With a follow up of 18 months, 16.6 percent of patients in study group and 24.4 percent in control group, who had initially shown response, died due to progressive disease. Patients in the study group tolerated MIC chemotherapy well. Toxicity was generally moderate and manageable. No therapy induced death occurred during the study and no dose reduction/ treatment modifications were required. Common toxicities encountered were nausea and vomiting, which were controlled by proper antiemetic therapy. Myelosuppression was frequent but moderate, and life threatening infections or hemorrhages were not observed. This study demonstrates that induction chemotherapy(MIC regime) and radical radiotherapy appears to be a good therapeutic approach for locally advanced NSCLC with manageable toxicities.
[ABSTRACT]   Full text not available   
  691 0 -
Priapism in a child with pelvic rhabdomyosarcoma, case report and review of literature.
T Raja, PM Shah, KM Patel, SN Shukla, BJ Parikh, AS Anand, CJ Desai, S Almel, M Delwadiya, Murali
September 1995, 16(3):188-191
Malignancy causing priapism is less common and hematological malignancies account for most of the cases both in adults and children. Most cases of priapism have no discernible cause. Solid tumours causing priapism account for about 8 percent of adult cases, while in children malignant solid tumours causing priapism are rare. In the english literature, rhabdomyosarcoma associated with priapism has not been reported in children , to the best of our knowledge. We present a case of pelvic rhabdomyosarcoma presenting with priapism.
[ABSTRACT]   Full text not available   
  617 0 -
Neo-adjuvant chemotherapy followed radiotherapy vs radiotherapy alone in squamous cell carcinoma oesophagus.
BN Savani, VK Gupta
September 1995, 16(3):162-167
In an ongoing randomized study, chemotherapy with cisplatin and Fluorouracil followed by radiotherapy was compared with radiotherapy alone in Squamous Cell Carcinoma Oesophagus. Between March 94 and Oct.94, 48 patients with Squamous Cell Carcinoma of the Oesophagus entered in the study. There were 24 patients each in CT+RT and RT arm respectively. There was one death because of Chemotherapy toxicity, 2 patients were lost to follow-up, one each in CT+RT and RT arm respectively. So 43 patients had completed prescribed treatment program and were followed for 2 months post treatment for assessment of immediate local tumor control and toxicity. Immediate post chemotherapy result showed complete tumor regression in 8(36.4 percent) and 10(45.5 percent)in the CT + RT arm and in 2(9.1 percent) in the RT arm(p0.05). At the end of treatment 85 percent of patients achieved complete dysphagia relief in CT + RT arm and 65 percent in RT arm(p0.05). Patients tolerated CT + RT protocol well with toxicity caused delay in CT in 3(12.5 percent) patients with no dose reduction. In RT arm not a single patient developed any grade 3 and 4 toxicity, these were mucositis(12 percent), vomiting (10 percent) and anemia(8 percent). This study shows that multimodel therapy is a better therapeutic option compared to RT alone in non-surgical management of Squamous Cell Carcinoma of the Oesophagus. Toxicity of CT is acceptable with good immediate tumor control. Long term follow-up of the study will give us exact idea about survival and recurrence pattern. Earlier systemic treatment may treat distant micrometastatic disease estimated to be present in as many as 85 percent of patients and smaller tumor bulk makes treatment more efficacious.
[ABSTRACT]   Full text not available   
  592 0 -
Erythroid blastic crisis in a case of chronic myeloid leukemia : a case report.
S Bajpai, SC Shinde, Y Badrinath, SA Barbhaya, CN Nair, P Kadam, SH Advani
September 1995, 16(3):174-176
We present here a case report of a chronic myeloid leukemia which evolved into a blastic crisis over a period of two years. On immunophenotyping the blasts were characterized as pure erythroid blasts showing positivity only for glycophorin antibody Cytogenetic study revealed presence of Ph chromosome.
[ABSTRACT]   Full text not available   
  573 0 -
Extraskeletal osteosarcoma.
SVSS Prasad, TG Sagar, V Maitreyan, U Majli
September 1995, 16(3):183-187
This report describes the presentation of an extraskeletal osteosarcoma in a 58 year old male, mimicking a soft tissue tumour. This patient was treated with local excision, radiation and systemic chemotherapy and is disease free, 2 years from diagnosis.
[ABSTRACT]   Full text not available   
  572 0 -
A new approach in experimental chemotherapy using drug-lectin combination.
C Ganguli, S Das
September 1995, 16(3):148-155
The efficacy of sequential treatment of anticancer drugs and plant lectins in enhancing the cytotoxic effects of antitumour agents and improving survival rates of the tumour bearing host were examined. The possiblity of reducing the toxic side effects of anticancer drugs by the use of lectus by reducing the total dose of the former was also examined.
[ABSTRACT]   Full text not available   
  563 0 -